Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial

The Lancet Oncology

Volumn 15, Issue 7, 2014, Pages 738-746

  Sartor, Oliver ^a   Coleman, Robert ^b   Nilsson, Sten ^c   Heinrich, Daniel ^d   Helle, Svein I ^e   O'Sullivan, Joe M ^f   Fosså, Sophie D ^g   Chodacki, Aleš ^h   Wiechno, Paweł ⁱ   Logue, John ^j   Widmark, Anders ^k   Johannessen, Dag Clement ^l   Hoskin, Peter ^m   James, Nicholas D ^n,o   Solberg, Arne ^p   Syndikus, Isabel ^q   Vogelzang, Nicholas J ^r   O'Bryan Tear, C Gillies ^s   Shan, Minghua ^t   Bruland, Øyvind S ^u   Parker, Christopher ^v   more..

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WESTON PARK HOSPITAL   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h Chomutov Hospital   (Czech Republic)

ⁱ INSTITUTE OF ONCOLOGY   (Poland)

^j CHRISTIE HOSPITAL   (United Kingdom)

^k UMEÅ UNIVERSITY   (Sweden)

^l ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^m MOUNT VERNON CANCER CENTRE   (United Kingdom)

ⁿ UNIVERSITY OF WARWICK   (United Kingdom)

^o UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^p TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^q CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^r Department of Hematology Oncology   (United States)

^s Algeta AS   (Norway)

^t BAYER CORPORATION   (United States)

^u UNIVERSITY OF OSLO   (Norway)

^v INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; DOCETAXEL; PLACEBO; RADIUM CHLORIDE RA 223; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE QUALITY; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORTHOPEDIC SURGERY; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SPINAL CORD COMPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIUM;

EID: 84901638475     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70183-4     Document Type: Article

References (22)

1. Coleman RE Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27:165-176.
2. Lange PH, Vessella RL Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev 1999, 17:331-336.
3. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
4. DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 2007, 15:869-876.
5. Roodman GD Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664.
6. Hagiwara M, Delea TE, Saville MW, Chung K Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis 2013, 16:23-27.
7. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458-1468.
8. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96:879-882.
9. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822.
10. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197.
11. Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012, 13:1210-1217.
12. Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis 2011, 14:177-183.
13. Xofigo (radium Ra-223 dichloride) injection, for intravenous use [package insert] 2013, Bayer HealthCare Pharmaceuticals Inc, Wayne, NJ.
14. Bruland OS, Nilsson S, Fisher DR, Larsen RH High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?. Clin Cancer Res 2006, 12(20 Pt 2):6250. 57s.
15. Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002, 62:3120-3125.
16. Henriksen G, Fisher DR, Roeske JC, Bruland OS, Larsen RH Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med 2003, 44:252-259.
17. Lewington VJ Bone-seeking radionuclides for therapy. J Nucl Med 2005, 46(suppl 1):38S-47S.
18. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013, 369:213-223.
19. Therneau T, Grambsch P, Pankratz V Penalized survival models and frailty. Computational and Graphical Statistics 2003, 12:156-175.
20. Sartor O, Hoskin P, Bruland OS Targeted radio-nuclide therapy of skeletal metastases. Cancer Treat Rev 2013, 39:18-26.
21. Vassiliou V, Bruland O, Janjan N, Lutz S, Kardamakis D, Hoskin P Combining systemic bisphosphonates with palliative external beam radiotherapy or bone-targeted radionuclide therapy: interactions and effectiveness. Clin Oncol (R Coll Radiol) 2009, 21:665-667.
22. Scher HI, Morris MJ, Basch E, Heller G End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol 2011, 29:3695-3704.